Key result
The presence of antiphospholipid antibodies was associated with a higher rate of restenosis after PTCA (40% vs 15%) and earlier occurrence compared to aPL negative patients.
Why the study?
Does the presence of antiphospholipid antibodies increase the risk of restenosis after PTCA in patients with ischaemic heart disease?
Cohort (n=60)
Does the presence of antiphospholipid antibodies increase the risk of restenosis after PTCA in patients with ischaemic heart disease?
Absolute Event Rate: 40% vs 15%
The presence of antiphospholipid antibodies is associated with a higher and earlier incidence of restenosis with recurrent ischemia after PTCA, independent of hypercoagulability markers.
No takes yet. Share an insight, caveat, or question.
aPL positivity was associated with higher restenosis after PTCA; leaves open whether screening improves outcomes in ischaemic heart disease.
Ludia et al. (1998) conducted a cohort in Ischaemic heart disease undergoing PTCA (n=60). Antiphospholipid antibodies (aPL) vs. aPL negative was evaluated on Restenosis. The presence of antiphospholipid antibodies was associated with a higher rate of restenosis after PTCA (40% vs 15%) and earlier occurrence compared to aPL negative patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: